KinOmega Biopharm Inc.

KinOmega’s story dates back to 2005

We're inspected and approved by Korean FDA in 2019. We're the FIRST Omega-3 manufacturer to get the KFDA cGMP in China, our API product show very good presence in Korea and the market share is up to 40%.

We built the Smart Factory in 2020. Highly automated and intelligent, the whole production line can be easily controlled with computer. Less workers but large prodcution capacity make KinOmega products more effecient, quality stable and price competitive.

We're inspected and approved by Japan PMDA and USFDA in 2022. We're the FIRST Omega-3 manufacturer to get the Japan PMDA cGMP in China, and also pass USFDA on-site inspection with "0" observation, which enable us to achieve very good API market share in these two countries.

We introduced the innovative Algae EPA and DHA project in 2023. Plant based Omega-3 is more friendly to the environment. Sourced from crude algae oil from fermentation process, refined by our state-of-art production line, KinOmega premium quality algae product guarantees controllable and sustainable Omega-3 sources for mankind health.

We keep expansion for Injectable Omega-3 API and softgel line in 2024. New available API enables KinOmega to supply to more domestic and oversea pharma enterprises, and softgel line let us better serve our valued customers with more choices. Our factory now covers an area of 80,000 square meters.